A Phase 1 Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 in Combination With Ranibizumab in Subjects With Wet AMD
Latest Information Update: 10 Jan 2025
At a glance
- Drugs Ranibizumab (Primary) ; Sozinibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; First in man
- Sponsors Opthea
Most Recent Events
- 07 Jan 2025 According to an Opthea media release, company announced publication of data from this study in the peer-reviewed journal Translational Vision Science & Technology (TVST), issued on December 19, 2024.
- 22 Jul 2019 According to an Opthea media release, data from this trial will be presented at the Ophthalmology Innovation Summit (OIS) in Chicago on Thursday, July 25th, 2019.
- 14 Sep 2018 Results published in the an Opthea Media Release